AI Assets filed for a 2 million share initial public offering, and said it applied to list on the Nasdaq Capital Market. The a British Virgin Islands business company, through its Singapore subsidiary ...
Mixue Group, which operates China’s largest bubble-tea chain, is planning to raise HK$3.45 billion ($444 million) in an ...
4d
ET Now on MSNHexaware Share Price Listing: 2nd largest IPO since TCS in IT sector! Check how stock fared on debutHexaware Technologies is a global digital and technology services company. Hexaware Technologies IPO was the second largest ...
KATHMANDU, Feb 12: Nepal Micro Insurance Company Limited (NMIC) is going to issue an Initial Public Offering (IPO) starting on February 23. The company, which has already issued and distributed the ...
However, some can find it challenging to understand the stock price history and number of shares owned following ... its 1980 initial public offering (IPO). The stock had several 2-for-1 splits ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
The initial public offering (IPO) of Hexaware Technologies shall open for bidding on Wednesday, February 12. The IT solutions player is offering its shares in the range of Rs 675-708 apiece.
US AI-related shares tanked. Mainland Chinese stock markets reopened on Wednesday after a weeklong holiday. DeepSeek's Chinese partners, including Merit Interact, Philisense Tech, and TRS Info ...
The company and selling shareholders aim to raise up to $421 million by offering approximately 21 million shares priced between ... comes at a time the U.S. IPO market is looking to recover ...
This time, the company plans to sell $1 billion worth of stock and hit an $11.5 billion valuation in its planned IPO. That’s how ... Tuesday of 47.5 million shares, at between $19 and $21.
Merck MRK0.34%increase; green up pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results